{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:49:11Z","timestamp":1759837751575,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Influenza subtypes such as H7 have pandemic potential since they are able to infect humans with severe consequences, as evidenced by the ongoing H7N9 infections in China that began in 2013. The diversity of H7 viruses calls for a broadly cross-protective vaccine for protection. We describe the construction of recombinant modified vaccinia virus Ankara (MVA) vectors expressing the hemagglutinin (HA) or neuraminidase (NA) from three H7 viruses representing both Eurasian and North American H7 lineages \u2013 A\/mallard\/Netherlands\/12\/2000 (H7N3), A\/Canada\/rv444\/2004 (H7N3), and A\/Shanghai\/02\/2013 (H7N9). These vectors were evaluated for immunogenicity and protective efficacy against H7N3 virus in a murine model of intranasal challenge. High levels of H7-, N3-, and N9-specific antibodies, including neutralizing antibodies, were induced by the MVA-HA and MVA-NA vectors. Mice vaccinated with MVA vectors expressing any of the H7 antigens were protected, suggesting cross-protection among H7 viruses. In addition, MVA vectors expressing N3 but not N9 elicited protection against H7N3 virus challenge. Similar outcomes were obtained when immune sera from MVA vector-immunized mice were passively transferred to na\u00efve mice prior to challenge with the H7N3 virus. The results support the further development of an MVA vector platform as a candidate vaccine for influenza strains with pandemic potential.<\/jats:p>","DOI":"10.1038\/s41598-018-23712-9","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T02:03:37Z","timestamp":1522289017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase"],"prefix":"10.1038","volume":"8","author":[{"given":"Clement A.","family":"Meseda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vajini","family":"Atukorale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackeline","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryna C.","family":"Eichelberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-0996","authenticated-orcid":false,"given":"Jerry P.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,29]]},"reference":[{"key":"23712_CR1","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/v6072735","volume":"6","author":"AF Altenburg","year":"2014","unstructured":"Altenburg, A. F. et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6, 2735\u20132761 (2014).","journal-title":"Viruses"},{"key":"23712_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","volume":"97","author":"A Volz","year":"2017","unstructured":"Volz, A. & Sutter, G. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. Adv Virus Res 97, 187\u2013243 (2017).","journal-title":"Adv Virus Res"},{"key":"23712_CR3","doi-asserted-by":"publisher","first-page":"e16247","DOI":"10.1371\/journal.pone.0016247","volume":"6","author":"A Hessel","year":"2011","unstructured":"Hessel, A. et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 6, e16247 (2011).","journal-title":"PLoS One"},{"key":"23712_CR4","doi-asserted-by":"publisher","first-page":"13300","DOI":"10.1128\/JVI.01532-14","volume":"88","author":"A Kamlangdee","year":"2014","unstructured":"Kamlangdee, A., Kingstad-Bakke, B., Anderson, T. K., Goldberg, T. L. & Osorio, J. E. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol 88, 13300\u201313309 (2014).","journal-title":"J Virol"},{"key":"23712_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1086\/517614","volume":"195","author":"JH Kreijtz","year":"2007","unstructured":"Kreijtz, J. H. et al. Recombinant Modified Vaccinia Virus Ankara-Based Vaccine Induces Protective Immunity in Mice against Infection with Influenza Virus H5N1. J Infect Dis 195, 1598\u20131606 (2007).","journal-title":"J Infect Dis"},{"key":"23712_CR6","doi-asserted-by":"publisher","first-page":"e107316","DOI":"10.1371\/journal.pone.0107316","volume":"9","author":"M Prabakaran","year":"2014","unstructured":"Prabakaran, M. et al. Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine. PLoS One 9, e107316 (2014).","journal-title":"PLoS One"},{"key":"23712_CR7","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","volume":"14","author":"JH Kreijtz","year":"2014","unstructured":"Kreijtz, J. H. et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial. Lancet Infect Dis 14, 1196\u20131207 (2014).","journal-title":"Lancet Infect Dis"},{"key":"23712_CR8","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1128\/JVI.00730-16","volume":"90","author":"A Kamlangdee","year":"2016","unstructured":"Kamlangdee, A., Kingstad-Bakke, B. & Osorio, J. E. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses. J Virol 90, 6771\u20136783 (2016).","journal-title":"J Virol"},{"key":"23712_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3201\/eid2106.150021","volume":"21","author":"RD de Vries","year":"2015","unstructured":"de Vries, R. D. et al. Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine. Emerg Infect Dis 21, 1086\u20131088 (2015).","journal-title":"Emerg Infect Dis"},{"key":"23712_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1086\/595984","volume":"199","author":"JH Kreijtz","year":"2009","unstructured":"Kreijtz, J. H. et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 199, 405\u2013413 (2009).","journal-title":"J Infect Dis"},{"key":"23712_CR11","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","volume":"368","author":"R Gao","year":"2013","unstructured":"Gao, R. et al. Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. N Engl J Med 368, 1888\u20131897 (2013).","journal-title":"N Engl J Med"},{"key":"23712_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1304617","volume":"370","author":"Q Li","year":"2014","unstructured":"Li, Q. et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 370, 520\u2013532 (2014).","journal-title":"N Engl J Med"},{"key":"23712_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1473-3099(17)30323-7","volume":"17","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis 17, 822\u2013832 (2017).","journal-title":"Lancet Infect Dis"},{"key":"23712_CR14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/infdis\/jiu528","volume":"211","author":"JH Kreijtz","year":"2014","unstructured":"Kreijtz, J. H. et al. A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. J Infect Dis 211, 791\u2013800 (2014).","journal-title":"J Infect Dis"},{"key":"23712_CR15","unstructured":"Earl, P., Cooper, N., Wyatt, L., Moss, B. & Carroll, M. In Current Protocols in Molecular Biology Vol. 3 (eds F. M. Ausubel et al.) 16.16.11\u201316.16.13 (John Wiley and Sons, Inc., 1998)."},{"key":"23712_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.virol.2005.06.002","volume":"339","author":"CA Meseda","year":"2005","unstructured":"Meseda, C. A. et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339, 164\u2013175 (2005).","journal-title":"Virology"},{"key":"23712_CR17","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s007050170002","volume":"146","author":"E Hoffmann","year":"2001","unstructured":"Hoffmann, E., Stech, J., Guan, Y., Webster, R. G. & Perez, D. R. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146, 2275\u20132289 (2001).","journal-title":"Arch Virol"},{"key":"23712_CR18","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1016\/j.vaccine.2012.03.033","volume":"30","author":"F Schmeisser","year":"2012","unstructured":"Schmeisser, F. et al. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine 30, 3413\u20133422 (2012).","journal-title":"Vaccine"},{"key":"23712_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1086\/344234","volume":"186","author":"CA Meseda","year":"2002","unstructured":"Meseda, C. A., Elkins, K. L., Merchlinsky, M. J. & Weir, J. P. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis 186, 1065\u20131073 (2002).","journal-title":"J Infect Dis"},{"key":"23712_CR20","doi-asserted-by":"crossref","unstructured":"Gao, J., Couzens, L. & Eichelberger, M. C. Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay. J Vis Exp (2016).","DOI":"10.3791\/54573"},{"key":"23712_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1750-2659.2009.00094.x","volume":"3","author":"MR Sandbulte","year":"2009","unstructured":"Sandbulte, M. R., Gao, J., Straight, T. M. & Eichelberger, M. C. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza and other respiratory viruses 3, 233\u2013240 (2009).","journal-title":"Influenza and other respiratory viruses"},{"key":"23712_CR22","doi-asserted-by":"publisher","first-page":"e1002081","DOI":"10.1371\/journal.ppat.1002081","volume":"7","author":"W Wang","year":"2011","unstructured":"Wang, W. et al. Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. PLoS Pathog 7, e1002081 (2011).","journal-title":"PLoS Pathog"},{"key":"23712_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jviromet.2008.07.015","volume":"153","author":"W Wang","year":"2008","unstructured":"Wang, W. et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. Journal of virological methods 153, 111\u2013119 (2008).","journal-title":"Journal of virological methods"},{"key":"23712_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jviromet.2010.02.009","volume":"165","author":"W Wang","year":"2010","unstructured":"Wang, W., Xie, H., Ye, Z., Vassell, R. & Weiss, C. D. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. Journal of virological methods 165, 305\u2013310 (2010).","journal-title":"Journal of virological methods"},{"key":"23712_CR25","doi-asserted-by":"crossref","unstructured":"Kwon, H. I. et al. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses. J Virol 91 (2017).","DOI":"10.1128\/JVI.02259-16"},{"key":"23712_CR26","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","volume":"12","author":"RD de Vries","year":"2016","unstructured":"de Vries, R. D. & Rimmelzwaan, G. F. Viral vector-based influenza vaccines. Hum Vaccin Immunother 12, 2881\u20132901 (2016).","journal-title":"Hum Vaccin Immunother"},{"key":"23712_CR27","doi-asserted-by":"publisher","first-page":"e49704","DOI":"10.1371\/journal.pone.0049704","volume":"7","author":"RB Couch","year":"2012","unstructured":"Couch, R. B., Patel, S. M., Wade-Bowers, C. L. & Nino, D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 7, e49704 (2012).","journal-title":"PLoS One"},{"key":"23712_CR28","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.vaccine.2009.01.116","volume":"27","author":"RJ Cox","year":"2009","unstructured":"Cox, R. J. et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27, 1889\u20131897 (2009).","journal-title":"Vaccine"},{"key":"23712_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jama.2015.7916","volume":"314","author":"LA Jackson","year":"2015","unstructured":"Jackson, L. A. et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Jama 314, 237\u2013246 (2015).","journal-title":"Jama"},{"key":"23712_CR30","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jama.2014.12854","volume":"312","author":"MJ Mulligan","year":"2014","unstructured":"Mulligan, M. J. et al. Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. Jama 312, 1409\u20131419 (2014).","journal-title":"Jama"},{"key":"23712_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.vaccine.2015.12.062","volume":"34","author":"W Cao","year":"2016","unstructured":"Cao, W. et al. A highly immunogenic vaccine against A\/H7N9 influenza virus. Vaccine 34, 744\u2013749 (2016).","journal-title":"Vaccine"},{"key":"23712_CR32","doi-asserted-by":"publisher","first-page":"8235","DOI":"10.1128\/JVI.01085-13","volume":"87","author":"PH Goff","year":"2013","unstructured":"Goff, P. H. et al. Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin. J Virol 87, 8235\u20138240 (2013).","journal-title":"J Virol"},{"key":"23712_CR33","doi-asserted-by":"publisher","first-page":"6798","DOI":"10.1016\/j.vaccine.2014.09.070","volume":"32","author":"TM Babu","year":"2014","unstructured":"Babu, T. M. et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 32, 6798\u20136804 (2014).","journal-title":"Vaccine"},{"key":"23712_CR34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/infdis\/jiv526","volume":"213","author":"M Sobhanie","year":"2016","unstructured":"Sobhanie, M. et al. Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). J Infect Dis 213, 922\u2013929 (2016).","journal-title":"J Infect Dis"},{"key":"23712_CR35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1086\/590913","volume":"198","author":"K Levie","year":"2008","unstructured":"Levie, K. et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198, 642\u2013649 (2008).","journal-title":"J Infect Dis"},{"key":"23712_CR36","doi-asserted-by":"publisher","first-page":"e12217","DOI":"10.1371\/journal.pone.0012217","volume":"5","author":"A Hessel","year":"2010","unstructured":"Hessel, A. et al. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS One 5, e12217 (2010).","journal-title":"PLoS One"},{"key":"23712_CR37","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","volume":"212","author":"AS Monto","year":"2015","unstructured":"Monto, A. S. et al. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. J Infect Dis 212, 1191\u20131199 (2015).","journal-title":"J Infect Dis"},{"key":"23712_CR38","doi-asserted-by":"publisher","first-page":"e88340","DOI":"10.1371\/journal.pone.0088340","volume":"9","author":"A Hessel","year":"2014","unstructured":"Hessel, A. et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One 9, e88340 (2014).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23712-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23712-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23712-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T04:01:43Z","timestamp":1671595303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23712-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23712"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23712-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2018,3,29]]},"assertion":[{"value":"11 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5364"}}